A double-blind randomized controlled trial of continuous intravenous Ketorolac vs placebo for adjuvant pain control after renal surgery.
Gwen M Grimsby, Sarah P Conley, Terrence L Trentman...
https://pubmed.ncbi.nlm.nih.gov/23058854/Actively Recruiting
Led by Phoenix Children's Hospital · Updated on 2026-08-12
166
Participants Needed
1
Research Sites
8 weeks
Total Duration
Researchers are evaluating the use of continuous infusion versus intermittent dosing of ketorolac for pain control in children who have undergone cardiac surgery and are in the pediatric cardiovascular intensive care unit CVICU. The study aims to find out if continuous infusion of ketorolac can reduce the need for opioid medications compared to the current standard of intermittent ketorolac injections. This is important because opioids can cause complications such as hemodynamic instability, dependency, withdrawal, and longer hospital stays, especially in children with congenital heart disease CHD. Participants will be randomly assigned to one of two groups. One group will receive a continuous intravenous infusion of ketorolac for 48 hours along with intermittent placebo infusions, while the other group will receive intermittent ketorolac doses every 6 hours plus a continuous placebo infusion for 48 hours. No additional nonsteroidal anti-inflammatory drugs NSAIDs other than aspirin will be given during the study period. The goal is to compare opioid use within the first 72 hours after surgery between these two approaches. During the study, participants will be monitored for pain control, opioid use measured by fentanyl dose equivalents, kidney function, bleeding events, and sedative requirements. These assessments will take place within 72 hours postoperatively. The study includes a screening period and close monitoring of drug administration and patient responses, with the overall participation lasting for the initial post-surgery recovery period where pain control is critical.
CONDITIONS
Continuous vs Intermittent Ketorolac for Pain Control in Peds CV Surgery
K
Kevin Engelhardt, MD
S
Samantha Stack, BS
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here
Phoenix Children's Hospital
Lead Sponsor
This table compares participation in this trial with other options available for this condition. The information is drawn from published research and the trial’s study details and is provided for educational purposes only.
| Factors | Continuous ketorolac infusion | Standard intermittent ketorolac regimen |
|---|---|---|
| What is it? | Continuous intravenous infusion of ketorolac given for 48 hours after congenital heart surgery in young children, with placebo given intermittently. | Standard intermittent ketorolac regimen, in which children receive repeated doses at intervals (with continuous infusion replaced by placebo), to control pain after surgery. |
| Role in the trial | Tested as the investigational treatment arm to evaluate whether continuous ketorolac reduces pain and opioid use after heart surgery. | Serves as the direct comparison group reflecting current practice, using standard interval ketorolac dosing. |
| Primary use | Used for pain management after pediatric congenital heart surgery, aiming to minimize opioid (fentanyl) requirements. | Conventional pain management following surgery in children, representing usual method for limiting or supplementing opioid use. |
| How it is given | Administered as a continuous intravenous infusion for 48 hours, started within 12-24 hours postoperatively. | Given as intermittent intravenous doses at defined intervals, with placebo infusion in place of continuous ketorolac. |
| Evidence status | Current evidence for continuous infusion is evolving; prior studies in similar settings suggest opioid-sparing effects, but data remain limited in pediatrics after cardiac surgery. | Intermittent ketorolac has demonstrated effective pain relief in children after cardiac surgery, with some studies reporting reduced opioid requirement; overall evidence is supportive though not universally conclusive. |
| Important limitations | Safety and efficacy data for continuous infusion in young children after cardiac surgery are still limited. Risks related to kidney injury or bleeding must be monitored closely. | While generally effective, risk for bleeding, kidney injury, and institutional differences in practice and patient selection limit the generalizability of intermittent ketorolac use. |
Disclaimer: This comparison is created with the help of artificial intelligence(AI) and may contain errors or missing information. It is not medical advice and does not mean one option is better or safer than another. Clinical trials are still being studied, and joining a trial is your choice. Please consult your healthcare professional before making any decisions.
You may qualify if you...
You will not qualify if you...
Duration - 2 to 4 weeks
Participants are screened for eligibility to participate in the trial.
Duration - 48 hours
Participants receive either a continuous infusion of ketorolac plus intermittent placebo or intermittent ketorolac plus continuous placebo infusion for 48 hours after heart surgery.
Regular monitoring during infusion
Duration - 72 hours
Participants are monitored for pain control, opioid use, kidney function, bleeding, and sedative needs up to 72 hours after surgery.
Assessments at regular intervals
Study Type
INTERVENTIONAL
Masking
TRIPLE
Allocation
RANDOMIZED
Model
PARALLEL
Primary Purpose
SUPPORTIVE_CARE
Number of Arms
2
Have more questions? Get in touch with our team for quick support
Gwen M Grimsby, Sarah P Conley, Terrence L Trentman...
https://pubmed.ncbi.nlm.nih.gov/23058854/Mindy N Cohen, Uwe Christians, Thomas Henthorn...
https://pubmed.ncbi.nlm.nih.gov/21233498/Brady S Moffett, Tiffany I Wann, Kathleen E Carberry...
https://pubmed.ncbi.nlm.nih.gov/16618297/J Britton, F D Martinez
https://pubmed.ncbi.nlm.nih.gov/8970395/Meredith K Jalkut
https://pubmed.ncbi.nlm.nih.gov/24441450/Tamara N Dawkins, Cynthia A Barclay, Rhonda L Gardiner...
https://pubmed.ncbi.nlm.nih.gov/19134246/J W Burns, H A Aitken, R E Bullingham...
https://pubmed.ncbi.nlm.nih.gov/1911008/T Onaka, K Yagi
https://pubmed.ncbi.nlm.nih.gov/2168320/Meredith L Howard, Alex N Isaacs, Sarah A Nisly
https://pubmed.ncbi.nlm.nih.gov/27580638/Anuja Gupta, Casey Daggett, Stacey Drant...
https://pubmed.ncbi.nlm.nih.gov/15365927/Phoenix Children's Hospital
Lead Sponsor